Literature DB >> 17884003

Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?

Ilse Krebs1, Werner Brannath, Carl Glittenberg, Florian Zeiler, Jerry Sebag, Susanne Binder.   

Abstract

PURPOSE: To compare the state of the posterior vitreous in exudative age-related macular degeneration (AMD) with eyes with nonexudative AMD and controls.
DESIGN: Prospective, observational case series.
METHODS: B-scan ultrasonography and optical coherence tomography (OCT) were performed in 163 eyes from 82 subjects older than 55 years, 50 eyes with exudative AMD, 57 with nonexudative AMD, and 56 control eyes. Main outcome measures were the number of eyes with complete posterior vitreous detachment (PVD) by ultrasound and the number of eyes with central vitreomacular adhesion by OCT.
RESULTS: By ultrasonography, 17 (34.0%) of 50 eyes with exudative AMD had PVD as compared with 41 (71.9%) of 57 eyes with nonexudative AMD (P = .00002) and 34 (60.7%) of 56 controls (P = .017). OCT detected persistent central vitreoretinal adhesion surrounded by a detached posterior vitreous cortex in 18 (36%) of 50 eyes with exudative AMD, significantly higher than in nonexudative AMD (4/57 [7%]; P < .0001) and in controls (6/56 [10%]; P = .002).
CONCLUSIONS: Persistent attachment of the posterior vitreous cortex to the macula may be another risk factor for the development of exudative AMD via vitreoretinal traction inducing chronic low-grade inflammation, by maintaining macular exposure to cytokines or free radicals in the vitreous gel, or by interfering in transvitreous oxygenation and nutrition of the macula. Inducing PVD may provide prophylactic benefit against exudative AMD.

Entities:  

Mesh:

Year:  2007        PMID: 17884003     DOI: 10.1016/j.ajo.2007.07.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  60 in total

1.  Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.

Authors:  David T Goldenberg; Frank J Giblin; Mei Cheng; Shravan K Chintala; Michael T Trese; Kimberly A Drenser; Alan J Ruby
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

2.  [The vitreoretinal interface and its role in the pathogenesis of vitreomaculopathies].

Authors:  J Sebag
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

Review 3.  [The role of the vitreous body in diseases of neighboring structures].

Authors:  K Gekeler; S Priglinger; F Gekeler; C Priglinger
Journal:  Ophthalmologe       Date:  2015-07       Impact factor: 1.059

4.  Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.

Authors:  Thomas Bertelmann; Marta Spychalska; Laura Kohlberger; Stefan Strodthoff; Michael Witteborn; Nadia Kicova; Ulrich Sachs; Sebastian Irle; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-12       Impact factor: 3.117

5.  Branch retinal vein occlusion and vitreovascular traction: a preliminary spectral domain OCT case-control study.

Authors:  Francisco J Ascaso; Esteban Padgett; Esther Núñez; Laura Villén; Andrzej Grzybowski; José A Cristóbal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03       Impact factor: 3.117

6.  Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration.

Authors:  Yoko Nomura; Hidenori Takahashi; Xue Tan; Shigeto Fujimura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-08-06       Impact factor: 2.447

7.  Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Ryo Terao; Kentaro Yuda; Kayo Kure; Tatsuya Inoue; Hiroshi Ohtsu; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-01-10       Impact factor: 2.447

8.  Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Thomas A Ciulla; Thomas A Cuilla; Gui-Shuang Ying; Maureen G Maguire; Daniel F Martin; Glenn J Jaffe; Juan E Grunwald; Ebenezer Daniel; Cynthia A Toth
Journal:  Ophthalmology       Date:  2015-03-29       Impact factor: 12.079

9.  Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane.

Authors:  Shuhei Kimura; Yuki Morizane; Shinji Toshima; Mika Hosogi; Fumiaki Kumase; Mio Hosokawa; Yusuke Shiode; Atsushi Fujiwara; Fumio Shiraga
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-08       Impact factor: 3.117

10.  Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.

Authors:  Hae Min Kang; Sung Jun Lee; Chul Gu Kim; Eun Jee Chung; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.